You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Cytokinetics reported revenue up 76% versus Q2, CMI market growth of 45% year-over-year, and new-to-brand share close to 45% after eight months on market; cash and investments totaled $1.6 billion.
Cytokinetics reported Mycorso Q3 net revenue of $44.5 million, up 76% from Q2, and remains on track to submit an FDA supplemental NDA for NHCM this quarter, with an FDA decision on MAPLE HCM data scheduled for November 14th.
Cytokinetics reported third-quarter 2026 revenue of $47.6 million, including $44.5 million in MYQORZO net product revenue, and expects to submit a Supplemental New Drug Application for aficamten in non-obstructive HCM in Q4 2026.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
TL;DR. Cytokinetics reported strong early Myqorzo launch momentum with Q2 U.S. net product revenue of $23.0M and 1,500 patients dispensed, alongside positive ACACIA-HCM Phase 3 results supporting a planned Q4 sNDA for non-obstructive HCM, while SG&A spend and full-year GAAP expense guidance were raised and net loss widened to $198.8M.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Metric | Latest | Period | YoY |
|---|---|---|---|
| Approximately 1,500 patients were dispensed MYQORZO | 1,500 | As of June 30, 2026 | — |
| Cash, cash equivalents and investments | $1.7B | As of June 30, 2026 | — |
| Over 700 unique healthcare providers prescribed MYQORZO | 700 | As of June 30, 2026 | — |
| Over 80% of patients on therapy were on paid prescription | 80% | As of June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CYTK
this stock
Cytokinetics Inc
|
$7.82B | -11.7% | -87.4% | — | 12.9% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.56B | +18.8% | +46.2% | 34.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$98.84B | +23.8% | +20.8% | 21.1 | 2.1% |
|
MRNA
Moderna, Inc.
|
$90.38B | +657.4% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$66.05B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Cytokinetics reported revenue up 76% versus Q2, CMI market growth of 45% year-over-year, and new-to-brand share close to 45% after eight months on market; cash and investments totaled $1.6 billion.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CYTK | +4.5% | -9.4% | -26.4% | -10.9% | -11.7% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | +2.0% | -8.2% | -26.9% | -10.7% | -22.3% |
